Sequential pancreas after kidney transplantation: is anti-lymphocyte induction therapy needed?
Stratta
R J
RJ
University of Tennessee-Memphis, Department of Surgery 38163-2116, USA.
D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D011183:Postoperative Complications / Q000453:epidemiology; D011292:Premedication; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D003404:Creatinine; D006442:Glycated Hemoglobin; D007166:Immunosuppressive Agents